Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.5
2.4
Journals
Healthcare
Special Issues
Eye Care and Vision Health Beyond 20/20
share announcement

Eye Care and Vision Health Beyond 20/20

A special issue of Healthcare (ISSN 2227-9032). This special issue belongs to the section "Nursing".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 1699

Special Issue Editor

Prof. Dr. Pinakin Gunvant Davey

E-Mail Website
Guest Editor
College of Optometry, Western University of Health Sciences, Pomona, CA 91766, USA
Interests: glaucoma; age-related macular degeneration; visual function; macular pigment optical density; carotenoids; intraocular pressure; corneal biomechanics; retinal nerve fiber layer; optical coherence tomography
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

I am delighted to serve as a Guest Editor on this Special Issue entitled “Eye and Vision Health Beyond 20/20”. The pun is indeed intended, as we expected 2020 to be an excellent year for us, but unfortunately COVID-19 stood in our way. This additionally broke the fallacy that 20/20 represents optimal vision and health. We emerged more robust than ever after COVID-19, and the science of telemedicine indeed took a quantum leap forward. I look forward receiving articles that discuss advances in imaging, new technology, novel therapies, and preventative medicine in eye care and vision health. I welcome both research and review articles, including research articles that have not fulfilled their hypothesis.

I look forward to an exciting and much-needed Special Issue that will equally interest individuals training in the field and experts.

Prof. Dr. Pinakin Gunvant Davey
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • macular degeneration
  • glaucoma
  • digital eye strain
  • vision therapy
  • diabetes
  • diabetic retinopathy
  • hypertension
  • dry eye syndrome

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

13 pages, 2458 KiB  
Article
Long-Term Results of Pars Plana Vitrectomy with Internal Limiting Membrane Peeling for Vitreomacular Traction Syndrome: A Prospective Investigation in Central Asian Population
by Gulnar Zhurgumbayeva, Dastan Kyrykbayev, Kairat Ruslanuly, Susanne Binder and Mukhit Kulmaganbetov
Healthcare 2025, 13(1), 44; https://doi.org/10.3390/healthcare13010044 - 30 Dec 2024
Viewed by 438
Abstract
Background: There is a lack of research on the clinical characteristics of vitreomacular traction (VMT) in the Central Asian population, which evaluates the visual recovery and macular hole closure outcomes of pars plana vitrectomy (PPV) with membrane peel in this population. Methods: This [...] Read more.
Background: There is a lack of research on the clinical characteristics of vitreomacular traction (VMT) in the Central Asian population, which evaluates the visual recovery and macular hole closure outcomes of pars plana vitrectomy (PPV) with membrane peel in this population. Methods: This long-term prospective cohort study, conducted at the Kazakh Eye Research Institute from June 2015 to December 2021 with a follow-up period until December 2022, included 1574 patients (1784 eyes) with VMT syndrome. Among the eyes, 724 (40.58%) had VMT, 620 (34.75%) had a lamellar macular hole (LMH), and 440 (24.66%) had a full-thickness macular hole (FTMH). Results: The FTMH group consisted of small (≤250 μm) holes in 14 (3.2%) eyes, medium (250–400 μm) holes in 79 (17.9%) eyes, and large (>400 μm) holes in 347 (78.9%) eyes. Significant improvements in visual acuity, retinal thickness reduction, and macular hole closure were observed in 98.79% of patients with LMH and 81.14% of patients with FTMH at 1.5 months after surgery. PPV with membrane peel resulted in improved clinical outcomes, including enhanced visual acuity and macular structure. Conclusions: These findings support the existing research indicating the efficacy and relative safety of this surgical approach for VMT, despite the potential risks of postoperative complications. Full article
(This article belongs to the Special Issue Eye Care and Vision Health Beyond 20/20)
►▼ Show Figures

Figure 1

Other

Jump to: Research

13 pages, 1065 KiB  
Study Protocol
Efficacy and Safety of Useul for Dry Eye Disease: Protocol for a Randomized, Double-Blind, Placebo-Controlled, Parallel, Phase 2 Clinical Trial
by Yee-Ran Lyu, O-Jin Kwon, Bongkyun Park, Hyun-A Jung, Ga-Young Lee and Chan-Sik Kim
Healthcare 2024, 12(23), 2383; https://doi.org/10.3390/healthcare12232383 - 27 Nov 2024
Viewed by 792
Abstract
Introduction: Dry eye disease (DED) is a very frequently encountered ocular disease, making it a growing public health burden. However, current treatments for DED present unmet medical needs owing to their side effects or ineffectiveness. Therefore, an effective and safe therapeutic agent to [...] Read more.
Introduction: Dry eye disease (DED) is a very frequently encountered ocular disease, making it a growing public health burden. However, current treatments for DED present unmet medical needs owing to their side effects or ineffectiveness. Therefore, an effective and safe therapeutic agent to manage DED is needed. Method and Analysis: We planned a phase 2, dose-finding, double-blind, randomized placebo-controlled trial to evaluate the efficacy and safety of two different doses of USL (Useul), the extract of Achyranthis Radix, compared with placebo, for DED. USL has been found to protect against DED by inducing tear secretion and improving corneal irregularity via anti-inflammatory effects, which will provide new therapeutic options. One hundred and twenty participants will be enrolled, after assessing the inclusion/exclusion criteria, at Daejeon University Daejeon Korean Medicine Hospital. Enrolled participants will be allocated to standard-dose USL, high-dose USL, or placebo groups in a 1:1:1 ratio and will be required to administer the trial medication twice a day for 12 weeks and visit the clinic five times. For efficacy outcomes, objective endpoints of fluorescein corneal staining score, tear break-up time, Schirmer’s test, and meibomian test and subjective endpoints of Ocular Surface Disease Index, visual analog scale, Standard Patient Evaluation for Eye Dryness-II, and biomarkers will be assessed throughout the trial. Safety will be assessed based on adverse events, vital signs, laboratory tests, visual acuity, and intraocular pressure. Discussion: Our study results are expected to provide clinical evidence for the use of DED as an effective and safe agent for DED. Full article
(This article belongs to the Special Issue Eye Care and Vision Health Beyond 20/20)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop